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Domenighetti AA, Mathewson MA, Pichika R, Sibley LA, Zhao
L, Chambers HG, Lieber RL. Loss of myogenic potential and fusion
capacity of muscle stem cells isolated from contractured muscle in
children with cerebral palsy. Am J Physiol Cell Physiol 315: C247–
C257, 2018. First published April 25, 2018; doi:10.1152/ajpcell.
00351.2017.—Cerebral palsy (CP) is the most common cause of
pediatric neurodevelopmental and physical disability in the United
States. It is defined as a group of motor disorders caused by a
nonprogressive perinatal insult to the brain. Although the brain lesion
is nonprogressive, there is a progressive, lifelong impact on skeletal
muscles, which are shorter, spastic, and may develop debilitating
contractures. Satellite cells are resident muscle stem cells that are
indispensable for postnatal growth and regeneration of skeletal mus-
cles. Here we measured the myogenic potential of satellite cells
isolated from contractured muscles in children with CP. When com-
pared with typically developing (TD) children, satellite cell-derived
myoblasts from CP differentiated more slowly (slope: 0.013 (SD
0.013) CP vs. 0.091 (SD 0.024) TD over 24 h, P  0.001) and fused
less (fusion index: 21.3 (SD 8.6) CP vs. 81.3 (SD 7.7) TD after 48 h,
P  0.001) after exposure to low-serum conditions that stimulated
myotube formation. This impairment was associated with downregu-
lation of several markers important for myoblast fusion and myotube
formation, including DNA methylation-dependent inhibition of pro-
myogenic integrin- 1D (ITGB1D) protein expression levels (50%
at 42 h), and ~25% loss of integrin-mediated focal adhesion kinase
phosphorylation. The cytidine analog 5-Azacytidine (5-AZA), a dem-
ethylating agent, restored ITGB1D levels and promoted myogenesis
in CP cultures. Our data demonstrate that muscle contractures in CP
are associated with loss of satellite cell myogenic potential that is
dependent on DNA methylation patterns affecting expression of
genetic programs associated with muscle stem cell differentiation and
muscle fiber formation.
cerebral palsy; contracture; integrins; myoblast; satellite cell
INTRODUCTION
Cerebral palsy (CP) is a neurologically nonprogressive con-
dition caused by a perinatal insult to the brain (22, 40).
Although the brain lesion is nonprogressive, children with CP
have dramatic and progressive changes to their skeletal mus-
cles including altered muscle transcriptional profile, change in
connective tissue composition, and reduced force-generating
capacity secondary to both central and peripheral factors (5,
51–53). CP is also associated with development of spasticity
(i.e., abnormal increase in muscle tone or stiffness), shorter
muscles, abnormal bony torsions, gait deviations, and devel-
opment of debilitating muscle contractures, which manifest as
a reduced range of joint excursion (4, 10, 21, 35). Given the
stable and high prevalence of 2–3 per 1,000 births, CP places
a significant and long-lasting burden on patients, families, and
society (6, 11, 57). Restoring muscle strength and function,
while managing spasticity and progression of muscle contrac-
ture, is the fundamental goal of rehabilitation and surgery in
children with CP. Conservative treatments include physical
and occupational therapies, as well as spasticity management
using focal or systemic drugs and surgical intervention to
release tendons, lengthen muscles, or correct bony deformities
(10, 16, 20, 24, 41). Despite the variety of potential interven-
tions among children with CP, one in three cannot walk, and
among those who can walk, one in six regularly use walking
aids and may lose the capacity to walk during adolescence
(40). Therefore, there is an urgent need for new innovative
therapeutic approaches to improving rehabilitation outcomes
and the quality of life in this patient population. Currently, the
biological causes for skeletal muscle impairment and develop-
ment of contractures in children with CP are largely unknown,
and there is much to be gained from understanding fundamen-
tal skeletal muscle adaptations at the cellular level.
Satellite cells (SCs), the muscle resident stem cells that
anatomically reside in their niche between the muscle fiber and
its basal lamina, are indispensable for postnatal muscle growth
and regeneration (17, 30, 31, 45). Cultured mononucleated
SCs, and their differentiation into fusion-competent myoblasts
and then into multinucleated myotubes, provide an excellent in
vitro model to study many of the complex changes that occur
during postnatal muscle tissue development and regeneration.
Our recently published work demonstrated a 60%–70% de-
crease of resident SC number in contractured muscle tissue in
children with CP (14, 50). Furthermore, we recently used
Pax7-DTA (Pax7CreER/;Rosa26DTA/) mice to reduce the
muscle resident SC number to the same extent as observed in
children with CP (28). Experiments on these mice showed that
stretch- and casting-induced sarcomere adaptation, muscle fi-
ber lengthening, ankle range of motion, and connective tissue
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homeostasis were all impaired after reduction of their SC pool.
This recapitulates some of the muscle phenotype observed in
young patients with CP and thus these data suggest that SC
pool depletion and decreased myogenic potential of SCs could
actually cause many of the muscles abnormalities in children
with CP. The purpose of this study was to measure the in vitro
myogenic potential of myoblasts derived from SCs isolated
from children with CP and to compare it to typically develop-
ing (TD) children (Table 1). Our results suggest that SCs
isolated from contractured muscles in CP have a decreased
capacity to fuse and to produce myotubes in vitro. This im-
pairment was associated with downregulation of the muscle-
specific integrin-signaling pathway that regulates myoblast
fusion during myotube formation. Interestingly, decreased ex-
pression of the integrin- 1D (ITGB1D) isoform was linked to
DNA hypermethylation of the CpG island located in the
promoter region of the ITGB1 gene. Furthermore, the cytidine
analog 5-azacytidine (5-AZA) induced demethylation of the
same promoter region and thus rescued ITGB1D expression
and improved myotube formation in CP cell cultures.
METHODS
Muscle biopsy collection. This study met the ethical standard of the
Declaration of Helsinki and was approved by the institutional review
board of the University of California, San Diego, Human Research
Protection Program. Participants were recruited into this study after
age-appropriate assent from children and written informed consent
from parents were obtained. CP children with diplegia or quadriplegia
underwent hamstring lengthening surgery involving the gracilis and
semitendinosus muscles whereas typically developing (TD) children
were recruited as a comparison group because they were undergoing
anterior cruciate ligament (ACL) reconstructive surgery but with no
previous history of neurological disorders. Children undergoing ACL
replacement have recovered from the initial injury without knee
swelling and demonstrate normal gait. Thus, for the purposes of this
study, they are considered normal controls, which is critical because
actual normal children’s muscle is nearly impossible to obtain. The
autograft in TD children was made using gracilis and semitendinosus
tendons, which were excised along with a portion of distal muscle that
was obtained as it was trimmed from the tendon. Biopsies from
children with CP and TD children were obtained from the distal
muscle portion near the musculotendinous junction. Exclusion
criteria for CP patients included: 1) previous traumatic leg injury
such as fractures, dislocations, or ligament tears; 2) surgery or drug
treatment (e.g., Botulinum toxin, Baclofen) to the leg within the
past 6 mo; and 3) dystonia, athetosis, or other involuntary move-
ments. Inclusion criteria included: 1) 3–18 yr of age, 2) diagnosis
of cerebral palsy, and 3) Gross Motor Function Classification
System (GMFCS) Levels I–V. All patients with CP had developed
a contracture requiring surgery, despite receiving conservative
treatment. Patients were classified based on clinical measures of
the GMFCS scale and popliteal angle. The GMFCS provides a
description of a child’s current self-initiated motor function (lower
level being associated with better motor function) and gives an
idea of the types of mobility aids a child may need in the future,
e.g., crutches, walking frames, or wheelchairs (23). Popliteal angle
is an assessment of hamstring muscle tone. The thigh is flexed on
the abdomen with one hand, and then the other hand straightens the
leg by pushing on the back of the ankle until there is firm resistance
to the movement. There is no definition of GMFCS or popliteal
angle for TD patients. On average, patients with CP were ~6 yr
younger than the TD control children (yr old: 9 (SD 4) CP vs. 15
(SD 1) TD, P  0.005, n  8/group; Table 1). TD children were
recruited as a comparison group because they were undergoing
ACL reconstructive surgery using a hamstring autograft and had no
history of neurological disorders. Surgery for TD patients took
place ~4 mo after the initial injury of their ACL. At this time, they
had no swelling, walked freely, and continued all activities of daily
living, with the exception of participating in intensive sports or
exercise. We believe that this level of activity for several weeks
before surgery suited the TD patients to be “controls” in our study.
SC isolation. SCs were isolated by fluorescence-activated cell
sorting (FACS) using a modification of the previously described
procedure (50). Briefly, gracilis or semitendinosus muscle biopsies
from TD and CP patients were digested in a collagenase-dispase
solution, mechanically disrupted with forceps, filtered twice, spun
at 600 g for 10 min, and resuspended in FACS buffer (pH 7.4
1 mM EDTA and 2.5% normal goat serum in PBS). Cells were
stained with anti-CD56 (neural cell adhesion molecule, clone
HCD56), which has previously been shown to reliably identify
myogenic Pax7  SCs (7, 50), anti-CD31 (clone EP3095), which
is a marker of endothelial cells, and anti-CD45 (ab-10559, Abcam),
which is a marker of leukocytes. CD31 and CD45 were combined
into a dump channel and the remaining CD56 cells were collected
using a FACSAria II (BD Biosciences, San Jose, CA). In this
study, SCs were defined as the population of cells that were
CD31/CD45/CD56. Gating was set to high stringency, includ-
ing only CD56 cells and excluding double positive cells. It is
possible that many SCs were discarded, but the population col-
lected was very pure and appeared homogeneous and highly
myogenic in culture. SC-derived myoblasts in culture (passages
P2–P4) were used for all experiments listed below.
Fusion and differentiation assays. Myoblast fusion and myotube
formation were examined in vitro using the iCELLigence RTCA
Instrument (ACEA Biosciences), which measures the electric imped-
ance of cells during growth without labeling. Electric impedance
measurement assays were previously used successfully to monitor
growth and formation of myotubes in vitro (39, 48). In our assays,
SC-derived myoblasts were grown in modified 0.5% gelatin-coated
8-well plates with microelectrodes on the bottom of each well for
impedance-based detection. Myoblasts (20,000) were seeded per well
(surface area 0.64 cm2), covering 60%–70% of well surface after
settling for 12 h. Cells were cultured at 37°C in a 5% CO2 atmosphere
using a high-serum medium containing Ham’s F10 (Corning) with
20% fetal bovine serum (from GIBCO), 10 mg/ml streptomycin, and
100 U/ml penicillin (GIBCO) and human recombinant bFGF (5 ng/ml,
Table 1. Characteristics of study participants
Patient Age Sex GMFCS Pop Angle Limbs Prev Surg BTX Baclofen
CP1 9 M 5 110 Q No No Yes
CP2 7 M 2 100 D No Yes No
CP3 8 M 2 100 D No Yes No
CP4 3 M 4 110 Q No Yes Yes
CP5 18 F 5 100 Q Yes No Yes
CP6 8 F 3 110 D No Yes Yes
CP7 10 M 4 135 Q Yes Yes Yes
CP8 8 F 3 120 D No Yes No
TD1 16 M NA NA NA No No No
TD2 15 M NA NA NA No No No
TD3 15 M NA NA NA No No No
TD4 14 F NA NA NA No No No
TD5 16 F NA NA NA No No No
TD6 15 M NA NA NA No No No
TD7 14 F NA NA NA No No No
TD8 18 F NA NA NA No No No
Baclofen, whether patient had exposure to baclofen (6 mo prior); BTX,
whether patient had exposure to botulinum toxin (6 mo prior); CP, cerebral
palsy; D, diplegia; F, female; GMFCS, Gross Motor Function Classification
System; M, male; NA, nonapplicable; Pop, popliteal; Prev surg, whether the
patient had previous surgeries (6 mo prior); Q, quadriplegia; TD, typically
developing. Age measured in years; popliteal angle measured in degrees.
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BD Biosciences) until they were ~90% confluent. Differentiation was
promoted by switching from high-serum to a low-serum DMEM
medium (GIBCO) containing 2% horse serum (GIBCO), 4.5 g/l
D-Glucose, L-Glutamine, 10 mg/ml streptomycin, 100 U/ml penicillin
(GIBCO), and 1 l/ml insulin solution (Sigma-Aldrich). Myotube
formation was associated with a significant increase in cell imped-
ance, measured as a baseline Cell Index (CI) increasing over time. For
myotube formation quantification, CI was monitored every 15 min for
up to 42 h after the switch to low-serum medium. Two to three
replicates of each culture were run at the same time and averaged.
Data were analyzed using the RTCA software from ACEA. After
normalization and measurement of a Delta Cell Index (DCI), the slope
of the curve generated, starting from the time of medium switch to the
time when the assay was stopped, was used to quantify “rates of
fusion and myotube formation” over time in CP versus TD samples
(Fig. 1, A and B). To validate this assay, myoblast fusion index
measurements and immunohistochemistry (see below) were per-
formed in parallel.
Immunostaining. Cells were cultured in 35-mm, low 60 -Dish
plates (Ibidi). Cultures were rinsed one time with PBS, fixed for 10
min with 4% paraformaldehyde, and rinsed three times with PBS.
Cells were then permeabilized for 10 min in 1	PBS supplemented
with 0.2% Triton X-100 (Sigma-Aldrich), washed three times with
PBS, and incubated in blocking solution (150 mM NaCl and 20 mM
Tris, pH 7.4) supplemented with 1% BSA for 1 h at room temperature
before incubation with primary antibodies against slow myosin heavy
chain (MYH7) (clone NOQ7.5.4D), -tubulin (clone E7), or pan-
vinculin (which detects both vinculin and metavinculin forms; clone
hVIN-1) diluted in blocking solution. Cells were incubated with
primary antibodies overnight at 4°C. After incubation, cells were
washed three times for 5 min with PBS and incubated with secondary
antibodies (all from Jackson ImmunoResearch) diluted into blocking
solution for 1–2 h at room temperature. Secondary antibody mixtures
also contained 4=,6=-diamidino-2-phenylindole (DAPI) and Alexa
Fluor 488 conjugate of wheat germ agglutinin (WGA, Thermo Fisher
Scientific) when appropriate. After washing three times with PBS for
5 min, cells were mounted using fluorescent mounting medium
(Vectashield). Microscopy was performed using a Leica TCS SP5
confocal microscope using the 	20 air objective and zoom rates
between one and three in sequential scanning mode when appropriate.
Fusion index. The fusion index was calculated 42 h after switch to
low-serum medium. It was defined as the total number of DAPI-
stained nuclei (excluding mono- and binucleated) in slow myosin
heavy chain (MYH7)-positive cells cells divided by the total number
of nuclei per field. The number of nuclei per myotube was established
by automated count of nuclei within every myotube per microscopic
field divided by the number of myotubes in the field, where a myotube
is defined as a MYH7-positive cell with at least three nuclei. For each
sample, the fusion index was measured using 5 microscopic fields/
35-mm cell culture dish, acquired on a Leica TCS SP5 confocal
microscope using the 20 	 air objective.
5-AZA treatment of cultured myoblasts. Myoblasts were seeded at
~13,000 cells/cm2 and were maintained in the same high-serum
medium up to 70%–80% of confluence. These proliferating cells were
then treated with 5-AZA (5 M, Sigma-Aldrich) for 24 h to induce
DNA demethylation before differentiation or not treated with 5-AZA
as a control. Differentiation was promoted by switching from high-
serum to the low-serum DMEM medium (GIBCO). Myotube forma-
tion was monitored and fusion indices were quantified 42 h after
differentiation on fixed and immunostained cell cultures. The 5-AZA
concentration of 5 M was selected as it was previously reported as
the optimal concentration to induce effects on differentiation without
cytotoxicity (27, 38, 55).
Western blotting. Proteins were extracted from cells by briefly
sonicating samples suspended in custom-made RIPA buffer (1.752 g
NaCl, 2 ml NP-40, 1 g deoxycholic acid, 1 ml 20% SDS, 6.67 ml 1.5
M Tris, pH 8, to 200 ml with ddH2O), followed by 4°C centrifugation
(10,000 g, table-top centrifuge with FA-45-24-11 rotor, Eppendorf) to
remove membrane components. Protein samples were stored in cus-
tom-made radioimmunoprecipitation assay buffer at 80°C. Total
proteins (15 g) were separated using NuPAGE 4%–12% Bis-Tris
gels with 20 	 NuPAGE MES or MOPS SDS running buffers and
antioxidants, according to manufacturer’s protocols (Novex-Life
Technologies). After separation, proteins were transferred to a nitro-
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Fig. 1. Decreased myoblast fusion and myotube forma-
tion in cerebral palsy (CP). A: example of a normalized
differentiation assay performed over ~42 h with the
iCELLigence RTCA system. Green curve represents a
typically developing (TD) myoblast preparation (aver-
age of 3 wells). Blue and red curves correspond to cell
preparations from two different CP children, CP1 and
CP2, under the same conditions (average of 3 wells per
sample). Differentiation was promoted by switching
from high-serum to low-serum medium. Myotube for-
mation is associated with a significant increase in cell
impedance. B: slopes of growth curves are used to
quantify the rate of fusion and myotube formation over
time; ***CP vs. TD, P  0.001; analysis by one-way
ANOVA (n  8/group). C: myoblasts from CP and TD
preparations were differentiated for 42 h and stained for
slow myosin heavy chain (MYH7) and a nuclear stain
(4=,6=-diamidino-2-phenylindole, DAPI). CP myotubes
appeared spindly, thin, and with fewer nuclei per myo-
tube. Gray scale panels show MYH7 staining as a single
channel. D: quantification of fusion index for CP and TD
myoblasts. Quantification was performed after 42 h of
differentiation; ***CP vs. TD, P  0.001; Analysis by
one-way ANOVA (n  8/group).
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cellulose membrane in a Tris-glycine buffer complemented with 20%
methanol. To visualize bands and detect transfer efficiency, mem-
branes were stained with Ponceau S membranes were then blocked in
a buffer containing 10 mM Tris, 0.15 M NaCl, 0.1% Tween-20, and
1% BSA and incubated with the primary antibody (1:500 to 1:1,000
dilution) overnight at 4°C. After washing, membranes were incubated
with peroxidase-conjugated secondary antibodies (1:1,000 dilution)
for 1 h at room temperature (all from Jackson ImmunoResearch) and
bands identified using chemiluminescence (ECL). Bands were ana-
lyzed by densitometry on a PXi imager (Syngene), and values are
expressed as arbitrary values of protein levels, normalized by total
proteins transferred on nitrocellulose membrane (as visualized with Pon-
ceau S). Primary antibodies used were: MYH7 (clone NOQ7.5.4D),
pan-vinculin (clone hVIN-1), SR Ca2-ATPase (SERCA1; clone
VE121G9), ITGB1D (custom-made, a kind gift from Dr. Robert S.
Ross, M.D., University of California, San Diego), total and phosphor-
ylated focal adhesion kinase (FAK; FAK antibodies Sampler Kit no.
9330, Cell Signaling Technology).
Real-time PCR. Myoblasts, pretreated or nontreated with 5 M
5-AZA for 24 h, were cultured in high serum medium until they
reached 80–90% confluence. After switch to low-serum medium,
myoblast preparations were allowed to differentiate for 24–72 h
before RNA extraction. Total RNA was isolated and purified from
myoblast cell culture preparations using Trizol reagent (Ambion, Life
Technologies) according to the manufacturer’s recommendations.
First-strand cDNA synthesis from purified RNAs and qPCR amplifi-
cation was performed using the GoTaq 2-Step RT-qPCR System kit
(Promega) according to manufacturer’s protocols. Resulting cDNAs
were subjected to SYBR Green-based real-time amplification using a
C1000 Thermal Cycler apparatus (Bio-Rad). Each PCR amplification
reaction (20-l volume) contained 100 ng of starting cDNA template.
Gene expression profiling during myoblast differentiation was inves-
tigated using predesigned 96-well gene panels for use with SYBR
Green (SABioscience) (Supplemental Material Tables S1 and S2;
Supplemental Material for this article is available online at the Journal
website). The panels utilized expertly designed and experimentally
validated PCR primers and assays and included three reference genes
for relative gene expression normalization and quantification: HPRT1,
TBP, and AP3DI. These reference genes were specifically validated
for our experimental treatment and conditions and were selected
among 15 experimentally tested candidates and analyzed using the
software packages Bestkeeper, geNorm, and Normfinder (15, 25).
Cycling conditions for SYBR Green primers consisted of an initial
step at 50°C (2 min) and a first denaturizing step at 95°C (2 min),
followed by 50 cycles of a thermal step protocol consisting of 95°C
(20 s), 60°C (20 s), and 72°C (20 s). A standard melt curve profiling
consisting of a 65°C–95°C thermal ramp was performed at the end of
each protocol. Gene expression quantification was performed using
Bio-Rad CFX Manager software. Positively and negatively regulated
genes were selected following a P  0.05 and a 2 or 0.5 expression
level, respectively. Functional gene classification was performed us-
ing the Database for Annotation, Visualization and Integrated Dis-
covery (DAVID; version 6.8; https://david.ncifcrf.gov/).
ITGB1 promoter methylation analysis. The promoter region of the
human ITGB1 gene contains CpG islands at position 32957344-
32958779 on chromosome 10 (band: 10p11.22; genomic size: 1436;
UCSC Genome Browser on Human Dec. 2013 GRCh38/hg38 assem-
bly). To test for ITGB1 promoter methylation, we used a Promoter
Methylation PCR Kit (Affymetrix). In this experiment, isolated
genomic DNA was digested with MseI restriction enzyme, and the
resulting DNA fragments were incubated with the DNA methylation
binding protein MeCP2/MBP. Methylated DNA fragments were iso-
lated with a spin column and then amplified with promoter specific
primers encompassing CpG sites. Real-time qPCR was used to am-
plify PCR products using similar cycling conditions reported above.
The presence of an amplified product indicated that a specific pro-
moter region was methylated in the genomic DNA sample. Two
primer pairs targeting different regions of the CpG island in the
ITGB1 promoter were designed: CpG 1F  CCTTCGCAGAGGAG-
GAAACT, CpG 1R  CTCCGGAAACGCATTCCTCT; CpG 2F 
GGTAGAAGTTGGCTTAGTGG, CpG 2R  ACGCGGTAAAAT-
GATACTAGAC. These primers encompassed DNA regions contain-
ing 15 and 19 CpG dinucleotides, respectively. An additional primer
pair encompassing a region of the promoter without CpG sites was
used as a negative control: CTRL F  CAGTTTTCTGTGCT-
GAGACTGG, CTRL R  CCCACTTAATGGATGTTCAAGC.
Statistics. Results are expressed as mean values with standard
deviation (SD). Analysis of variance (ANOVA), both one-way and
two-way, was used to test for differences (P  0.05) between CP and
TD groups (i.e., “condition”), and other independent variables, such as
“time course” or “treatment.” When statistical significance was
achieved, post hoc analysis using Tukey’s t-test with the Bonferroni
correction was applied. Linear regression quantified the correlation
between iCELLigence-generated slope and fusion indices (Fig. 2).
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Fig. 2. Linear regression of electric impedance measurements and fusion index.
A significant correlation between these values was observed. A: regression
analysis for all the values (CP and TD combined); R2  0.92, P  0.0001. B:
regression analysis for separated TD (squares) and CP (triangles) values; TD
(R2  0.68, P 0.01), CP (R2  0.77, P 0.004). Squares (TD) and triangles
(CP) are numbered from 1 to 8. These numbers correlate with patient identi-
fication numbers (e.g., number 1 next to a square  patient TD1). All three
analyses showed a significant correlation between electric impedance measure-
ments and fusion index, thus validating the impedance method. CP, cerebral
palsy; TD, typically developing.
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Analysis was performed using software package JMP13 Pro (SAS).
RESULTS
Impaired myoblasts fusion and myotube formation in CP cell
cultures. Cell impedance measurements over a 42-h period
demonstrated that rates of fusion and myotube formation were
decreased by ~85% in CP cultures compared with TD (slope:
0.013 (0.013 SD) CP vs. 0.091 (0.024 SD) TD, P  0.001)
(Fig. 1, A and B). Analogous measures of fusion index showed
that there was a ~74% decrease of fusion index in CP myoblast
cultures compared with TD, 42 h after differentiation (21.3 (8.6
SD) CP vs. 81.3 (7.7 SD) TD, P  0.001) (Fig. 1, C and D).
Linear regression showed a highly significant correlation be-
tween electric impedance measurements and fusion index
(R2  0.92, P  0.001, CP and TD values combined), vali-
dating the slope of the curves generated by impedance
measurements as a valid assay to quantify fusion and myo-
tube formation in vitro (Fig. 2).
Immunostaining of cultured myotubes was used to investi-
gate morphological changes in CP versus TD cell cultures after
42 h of differentiation. Cultures from the two groups differed
dramatically, with more mononucleated myoblasts and fewer
thin, spindly myotubes forming in CP cultures compared with
the many thick and highly multinucleated myotubes in TD
cultures (Fig. 1C and Fig. 3). Western blots showed significant
downregulation of important protein markers of myoblast dif-
ferentiation and myotube maturation in CP cultures, including
MYH7, metavinculin (MV), and the SR Ca2-ATPase
SERCA1/ATP2A1 after both 4 h and 42 h of differentiation in
low-serum medium (Fig. 4). Together, these data demonstrate
significant changes in fusion capacity and myotube formation
in CP myoblasts compared with TD. The high expression level
of markers such as MYH7, MV, and SERCA1/ATP2A1 in TD
cell cultures after 48 h indicated that these cells differentiated
faster and matured further down the myogenic pathway com-
pared with CP cultures.
Gene expression profiling during myoblast differentiation in
CP. Real-time qPCR was used to analyze the expression of a
curated panel of 85 genes that were previously shown to be
involved in myogenesis and skeletal muscle remodeling. Our
data showed that among 85 genes investigated, 42 were sig-
nificantly downregulated, and 9 were significantly upregulated
in CP cell cultures compared with TD 24 h after differentiation
(Supplemental Table S1). Among the downregulated candi-
dates were genes involved in the scaffolding and contractile
system of the muscle fiber (e.g., ACTA1, ACTA2, TNNI3, DES,
TPM1), myogenic factors (e.g., MEF2C, MEF2A, MYF5,
MYF6, CDK5, PAX3), vesicle trafficking (CAV1, CAV3),
mitogen-activated protein kinase (MAPK14), Wnt/-catenin,
and sonic hedgehog signaling (CTNNB1, SHH), and members
of the integrin signaling pathway (ITGA7, ITGB1, ITGAV,
CAV3). These data suggest that loss of myogenic potential
could be driven by a global downregulation of genes and
signaling pathways involved in myoblast fusion and muscle
fiber maturation in CP.
Downregulation of the integrin signaling pathway during
myoblast differentiation in CP. One molecule that mediates
integrin receptor signaling is the protein tyrosine kinase FAK.
Phosphorylation of FAK is transiently increased during myo-
genic differentiation, and inhibition of this process blocks
myoblast fusion (42). Protein analysis showed significant sup-
pression of ITGB1D levels (Fig. 5, A and B) and FAK phos-
phorylation at residues Y576–7 and Y925 in CP myoblasts
after 4 and 42 h of differentiation in low-serum medium (Fig.
5, D and E). No differences were noted for total FAK or
autophosphorylating FAK Y397 levels between CP and TD
TD1 CP2CP1
100 µm
TUBB
TD1 CP 2CP1
100 µm
VCL+MV
Fig. 3. Impaired fusion and myotube formation in cerebral palsy (CP) myoblast cultures. Immunofluorescence stain for the same typically developing (TD) and
CP (CP1 and CP2) myotube preparations shown in Fig. 1A. Grayscale panels show myoblast preparations differentiated for 42 h and then immunostained for
-tubulin (TUBB) or pan-vinculin, which detects vinculin (VCL) and metavinculin (MV).
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preparations, even though myoblast differentiation between 4
and 42 h was associated with an increase of FAK Y397 in both
CP and TD cell preparations (Fig. 5, A and C). These data
demonstrate that loss of myogenic potential and gene repres-
sion in CP myoblasts was associated with impairment of
integrins signaling during myotube formation in vitro.
5-AZA rescues ITGB1D expression and promotes myotube
formation in CP. The ITGB1D isoform is upstream of FAK as
an integrin receptor -subunit and is also regulated at the gene
level by FAK phosphorylation, which suggests that bidirec-
tional signaling could affect the ITGB1D–FAK pathway dur-
ing myoblast fusion (42). To further investigate potential
mechanisms that could inhibit ITGB1D expression during
myoblast fusion and myotube formation in CP, we performed
a DNA methylation analysis of the promoter region of the
human ITGB1 gene. DNA methylation is an epigenetic mech-
anism used by cells to silence gene expression in a mitotically
inheritable fashion. Changes in DNA methylation of muscle-
specific genes as well as in gene promoter and enhancer
regions enriched for CpG dinucleotides (CpG islands) play a
critical role in regulating myogenic differentiation in SCs (8, 9,
29). DNA methylation analysis of the CpG island located in the
promoter region of the ITGB1 gene showed a ~sevenfold
increase in promoter DNA methylation levels in CP myoblasts
after 24 h of differentiation (Fig. 6A). A 24-h pretreatment of
myoblast cultures with 5 M of demethylating agent 5-AZA
before differentiation was sufficient to demethylate the CpG
island in the ITGB1 promoter region (Fig. 6A) and increase
ITGB1D protein expression levels in differentiating CP cul-
tures (Fig. 6, D and E). Morphologically, 24 h of 5-M 5-AZA
pretreatment of myoblast cultures was sufficient to increase the
fusion index more significantly in CP myoblasts (200% in-
crease, 16.0 (4.9 SD) CP vs. 48.1 (9.6 SD) CP-AZA after 48 h)
compared with TD myoblasts (18% increase, 75.4 (6.6 SD) TD
vs. 89.4 (5.8 SD) TD-AZA after 48 h) (Fig. 6, B and C).
Differential gene expression profiling after 5-AZA treatment
in CP cell culture. To investigate whether additional signaling
pathways and genes were affected by 5-AZA treatment, real-
time qPCR was used to analyze the expression of 91 genes
involved in myogenesis, neurogenesis, and adipogenesis in
fusing CP myoblasts after 24 h of pretreatment with 5 M of
5-AZA (Supplemental Table S2). We found that 43 genes were
significantly upregulated and 7 genes were significantly down-
regulated in cultures pretreated with 5-AZA compared with
nontreated CP cultures after 48–72 h of differentiation. Several
candidate genes that were found to be initially downregulated
in differentiating CP cultures when compared with TD (Sup-
plemental Table S1) showed a pattern of upregulation after
5-AZA treatment in CP (ACTA1, BMI1, CAV3, DES, FOXO1,
ITGA7, ITGB1, MEF2A, MEF2C, MET, MYF5, MYF6,
NOTCH2, PAK1, PAX3, PPARA, PPARD, SHH, SIX1). Also,
5-AZA pretreatment led to upregulation of transcription regu-
lators involved in myogenesis and other signaling pathways
(BMI1, SIX1, SIX4, EGR3, FOXO1, MAPK14, MEF2A,
MEF2C, MYF5, MYOG, NEUROD2, NOTCH2, PAX3,
PAX7, PPARA, PPARD, PPARG, RPBJ, RARA). Specific
signaling pathways were also upregulated, including NOTCH
(DLL1, JAG1, JAG2, NOTCH2, RPBJ) and the integrin and
focal adhesion pathways (BCL2, MET, ACTN2, CAV3,
ITGA7, ITGB1, PAK1). Interestingly, upregulation of myo-
genic factors was also associated with upregulation of factors
potentially involved in regulatory networks of other differen-
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Fig. 4. Protein expression shows decreased
myotube maturation in cerebral palsy (CP).
A: representative Western blots showing dif-
ferential expression of slow myosin heavy
chain (MYH7, bands at ~223 kDa), vinculin
(VCL, lower band, ~120 kDa), and metavincu-
lin (MV, upper band, ~145 kDa) on the same
membrane, SR Ca2-ATPase 1 (SERCA1,
~110 kDa), and total protein load (bands in
the 5–25 kDa range). Protein analysis was
performed in CP and typically developing
(TD) cell preparations 4 h (4h) and 42 h (42h)
after medium switch. B: protein quantifica-
tion for MYH7; *CP vs. TD, P  0.0001;
Analysis by two-way ANOVA (n 6/group). C:
protein quantification for MV; *CP vs. TD, P
0.0001, **4 h vs. 42 h, P  0.0001; Analysis
by two-way ANOVA (n  6/group). D: pro-
tein quantification for VCL; **4 h vs. 42 h,
P 0.0001, #CP after 42 h, P 0.0001, Anal-
ysis by two-way ANOVA (n 6/group). E:
protein quantification for SERCA1, *CP vs.
TD, P 0.0001, **4 h vs. 42 h, P 0.0001,
#CP after 42 h, P  0.0009; Analysis by
two-way ANOVA (n  6/group). Only sig-
nificant P values are reported.
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tiation programs, including neurogenesis and adipogenesis
(NEUROD2, PPARG) (18, 19). Together, these data suggest
that downregulation of integrin ITGB1D-FAK signaling path-
way and decreased myogenic potential of differentiating myo-
blasts may be dependent on small or large-scale changes in
DNA methylation patterns affecting gene expression and acti-
vation of promyogenic signaling pathways in these cells.
DISCUSSION
This study provides compelling evidence that myoblasts
derived from SCs isolated from contractured CP muscle have
a decreased capacity to fuse and to produce myotubes in vitro.
This impairment is associated with downregulation of the
muscle-specific integrin signaling pathway that regulates myo-
blast fusion during myotube formation. Decreased expression
of the integrin- 1D (ITGB1D) isoform during differentiation
is linked to DNA hypermethylation of the CpG islands located
in the promoter region of the ITGB1 gene. Twenty-four-hour
pretreatment of CP myoblasts with the cytidine analog 5-AZA
was sufficient to demethylate the same promoter region, res-
cuing ITGB1D expression and improving myotube formation
during differentiation. Taken together, these data demonstrate
that muscle contractures are associated with decreased myo-
genic potential of SCs in children with CP. Importantly, as
demonstrated by 5-AZA treatment, this loss may be linked to
changes in DNA methylation patterns affecting expression of
genetic programs associated with SC differentiation and mus-
cle fiber formation in CP.
The myoblast fusion process is a highly complex, integrated
network involving coordination and crosstalk of many signal-
ing pathways, including multiple adhesion molecules, trans-
membrane receptors, signaling pathways, and timely activation
or inhibition of different genetic programs under control of
various transcription factors (1, 26). Our gene expression
analyses supported this view. In this study, we showed that the
integrin signaling pathway is one of the pathways affecting
myoblast fusion in CP. Integrins play a significant role in
multiple aspects of skeletal muscle homeostasis, including
maintenance of the SC niche, myoblast fusion, assembly of
costameres and sarcomeres, development of the myotendi-
nous and neuromuscular junctions, transduction of mechan-
ical signals that lead to cytoskeletal rearrangements, and
changes in gene expression (43, 44, 47, 54, 58, 61). Signal-
ing through integrin-mediated FAK phosphorylation during
myogenesis regulates the actin cytoskeleton, focal adhe-
sions, Wnt, and MAPK signaling. It also causes overexpres-
sion of CAV3 and ITGB1D genes, which are some of the
proteins involved in myoblast fusion whose gene expression
was downregulated in CP myoblasts during differentiation
(34, 42). Despite this strong evidence for a role of integrin
signaling, it is fair to assume that impairment in other
signaling pathways involved in myoblast fusion and myo-
tube formation (e.g., TMEM8C/Myomaker, Rho GTPases,
MAPKs, calcineurin- NFATc2, NF-
B, WNT, MMPs) may
have significantly contributed to the decrease in myogenic
potential of CP myoblasts (26, 37).
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Fig. 5. Impaired integrin signaling during
myoblast fusion and differentiation in cere-
bral palsy (CP). A: representative Western
blots showing differential expression of in-
tegrin -1D (ITGB1D, bands at ~116 kDa),
focal adhesion kinase (FAK) phosphorylated
at residue Y397 (FAK Y397, ~125 kDa),
FAK phosphorylated at Y576/7 residues
(FAK Y576/7, ~125 kDa), FAK phosphory-
lated at Y925 residue (FAK Y925, ~125
kDa), total FAK protein levels (FAK TOT,
~125 kDa), and total protein (bands in the
5–25 kDa range). Protein analysis was per-
formed in CP and typically developing (TD)
cell preparations, 4 h (4h) and 42 h (42h)
after high- to low-serum medium switch. B:
protein quantification of ITGB1D; *CP vs.
TD, P  0.0001; #CP after 42 h, P  0.01,
analysis by two-way ANOVA (n  8/
group). C: protein quantification for FAK
Y397, normalized over FAK TOT; **4 h vs.
42 h, P  0.025, analysis by two-way
ANOVA (n  6/group). D: protein quantifi-
cation for FAK Y576/7, normalized over
FAK TOT; *CP vs. TD, P  0.0001, **4 h
vs. 42 h, P  0.0001, #CP after 42 h, P 
0.034, analysis by two-way ANOVA (n 
6/group). E: protein quantification for FAK
Y925, normalized over FAK TOT, *CP vs.
TD, P  0.0001, **4 h vs. 42 h, P  0.0001,
#CP after 42 h, P  0.009, analysis by
two-way ANOVA (n  6/group). Only sig-
nificant P values are reported.
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We also identified DNA methylation as a possible mecha-
nism that adversely affects gene expression and impairs myo-
blast fusion in CP. This was confirmed by pretreatment of
myoblast cultures with the demethylating agent 5-AZA, which
improved differentiation in culture. Previous reports suggested
that expression of specific key transcriptional regulators during
myogenesis (MyoD, Myogenin, Myf5) were significantly af-
fected by DNA methylation. Published studies using C2C12,
human myoblasts, and/or embryonic stem cells showed that
proliferating myoblasts treated with 5-AZA exhibited in-
creased expression of muscle-specific genes, enhancing myo-
tube maturation, whereas DNA hypomethylation in gene pro-
moters was necessary for proliferating myoblasts to progress to
the myotube stage (8, 27, 38, 56). For these reasons, we
propose that hypermethylation of gene promoter regions asso-
ciated with myoblast fusion in CP prevented these cells from
proceeding through the myogenic program, resulting in impair-
ment of muscle fiber formation.
On a broader scale, genome-wide DNA methylation studies
showed that the majority of the DNA methylome remained
relatively preserved during myogenic differentiation of adult
satellite cells into myotubes (8, 56). Interestingly, a recent
publication showed that the enzymatic procedures used to
isolate and to sort satellite cells from adult tissue induced major
transcriptional changes accompanied by histone modifications
in these cells but did not involve significant alterations in DNA
methylation patterns (33). These data suggest that DNA meth-
ylation is a very stable epigenetic “imprint” that is preserved in
differentiated postmitotic tissue, as well as in tissue-committed
adult stem cells (e.g., satellite cells). For these reasons, we
speculate that the specific hypermethylation pattern that we
observed on the promoter region of the ITGB1 gene in CP cell
cultures represents a pathologic change of the early establish-
ment of an epigenetic memory to keep cell fate commitment
through the inheritance and maintenance of DNA methylation
patterns during postnatal development. If confirmed, this
would suggest that the impairment of myogenesis in contrac-
tured CP muscle could be the result of epigenetic and tran-
scriptomic changes affecting development and commitment of
early/embryonic muscle progenitors into Pax7-dependent adult
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Fig. 6. 5-Azacytidine (5-AZA) rescues, integ-
rin- 1D (ITGB1D) expression and promotes
myotube formation in cerebral palsy (CP). A:
DNA methylation analysis of the CpG island
located in the promoter region of the human
ITGB1 gene in differentiating CP and typically
developing (TD) myoblasts, pretreated (CP-
AZA) or nonpretreated (CP, TD) with cytidine
analog 5-AZA. Analysis was performed semi-
quantitatively using “fold-change” estimates,
where the nontreated TD group (TD) was set to
the value of 1; ***TD vs. CP; ***CP vs. CP-
AZA, P  0.001; analysis by one-way ANOVA
(n  4/group). B: immunofluorescence staining
for TD and CP myotube preparations, nontreated
or pretreated with 5-AZA (AZA). Myoblasts
were differentiated for 42 h and then stained for
myosin heavy chain 7 (MYH7; in red), and
counterstained for membrane marker wheat germ
agglutinin (WGA; in green) and nuclear marker
DAPI (in blue). Gray scale panels show MYH7
staining as a separate channel. C: quantification
of Fusion Index for CP and TD myoblasts non-
treated or pretreated with 5-AZA (AZA).
Quantification was performed after 42 h of dif-
ferentiation; *nontreated vs treated (AZA),
P  0.0001; **CP vs TD, P  0.0001; #CP
treated with AZA, P  0.02, analysis by two-
way ANOVA (N  4/group). D: protein quanti-
fication for ITGB1D by Western blotting in non-
treated (CP) and pretreated (CP  AZA) myo-
blast cultures after 42 h differentiation; ***P 
0.001, analysis by one-way ANOVA (n 
4/group). E: representative Western blots show-
ing differential expression of ITGB1D bands at
~116 kDa), in CP preparations nontreated (CP)
or pretreated with 5-AZA (CP  AZA). Only
significant P values are reported.
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satellite cells, thus preceding the development of muscle con-
tracture. An experimental analysis of DNA methylation and
myogenic potential of these cells isolated at different develop-
mental stages of CP using an experimental model (e.g., before
and after brain injury in an animal model) could establish
causality between epigenetic modifications and postnatal de-
velopment of muscle contractures. One may also envision a
clinical study where comparative methylation analyses could
be performed on DNA extracted from serial blood samples
obtained from developing children with CP. For therapeutic
purposes, it is important to determine the genomic locations
where DNA methylation affects myogenesis and myoblast
fusion in CP and to establish whether demethylating agents like
the cytidine analog 5-AZA could be used therapeutically to
promote muscle development and treat muscle contractures in
this patient population.
Future research will provide additional insight into the use of
5-AZA and its effects on muscle SC. For one, the clinical
significance of a decreased myogenic potential of SCs in CP
would be strengthened further by establishing a positive cor-
relation between the extent of in vitro myoblast dysfunction
with clinical parameters used to establish severity of contrac-
tures and gross motor function. This study relied on tissue
samples from eight study subjects per group, and future studies
with greater numbers of study subjects will further strengthen
the relationship between in vitro biological observations and
clinical parameters. Additionally, it would be important to
investigate whether a decrease in myoblast homeostasis in cell
culture is associated with a reduced capacity to regenerate
functional muscle fibers after injury or surgical procedures
using an in vivo model.
Overall, our findings suggest a new direction in the study of
human muscle contractures by demonstrating the impact that
impaired SC homeostasis plays on postnatal muscle growth
and repair in children with CP. Under physiological conditions,
skeletal muscle length increases as a result of the longitudinal
growth of the component muscle fibers leads to a gain in
muscle excursion and force generation (32). During the length-
ening process, sarcomeres are added in series at the ends and
sides of growing myofibrils by mechanisms of SC fusion and
muscle fiber hypertrophy (2, 46, 59). In particular, the ends of
skeletal muscle fibers and the myotendinous junction (the
connection site between tendon and muscle fibers) are sug-
gested to be rich in proliferating SCs and the preferential site
for SC fusion and overall longitudinal muscle growth (3, 60).
In children with CP, we suggest that the increase in muscle
length and volume required to keep up with the changes in
bone length during development is impaired, leading to mus-
culoskeletal impairments that exacerbate with age. These im-
pairments include shorter muscles and development of muscle
contractures that significantly affect joint excursion and move-
ment (4, 21, 35). Decreased capacity of the resident SC
population to participate in new muscle fiber formation or
repair following injury could directly impact postnatal devel-
opment and promote contractures in CP. At the cellular level,
muscle tissue complications in some children with CP are
associated with a ~40% reduction in serial sarcomere number,
i.e., the number of sarcomere units along the length of a fiber,
leading to sarcomere lengthening and overstretching (36, 52).
We previously demonstrated that these sarcomeric properties
were associated with altered muscle transcriptional profiles,
increased connective tissue, and a 60%–70% depletion of the
resident SC number (14, 50, 53). Even though the relationship
between sarcomere length, contractures, and SC homeostasis is
still not fully understood, we speculate that in CP, fewer cells
would successfully fuse with fibers and participate in muscle
formation as children grow, leading to “stretched” muscle
fibers with longer sarcomeres as previously reported (52). This
possibility is supported by recent experimental work showing
that stretch- and casting-induced sarcomere adaptation, muscle
fiber lengthening, ankle range of motion, and connective tis-
sue homeostasis were all impaired in mice with a preemptive
60%–70% deletion of their SC number (28). Furthermore,
other studies established that impairment in SC function as a
source of new myonuclei for nascent or regenerating fibers
leads to diminution of the SC pool, changes in the tissue
microenvironment, and increased tissue fibrosis, especially
during aging or progression of muscle dystrophies (12, 13, 49).
The difference in age between groups is a confounding
factor within this study as it was impossible to age match the
two groups. However, importantly, the impaired myogenic
potential of satellite cell-derived myoblasts in the younger
population of children with CP may actually be an underesti-
mate of the difference between groups, as younger children
would be expected to have a greater satellite cell function and
myogenic potential based solely on age. Thus, our results
suggest a mechanism whereby the myogenic potential of sat-
ellite cell-derived myoblasts could limit muscle growth and
repair in patients with CP.
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